(Now accepting patients)
The advancement of injection options for a wide range of joint, ligament, and muscle/tendon conditions has grown exponentially over the last decade. There has been a paradigm shift from performing “blind” injections (palpation guided) using traditional cortisone and/or hyaluronidase (lubricant) solutions to more precise ultrasound guided injections using more naturally occurring “biologics.” These cell- and tissue-based options include a smorgasbord of solutions frequently obtained from the patient’s own blood or tissue. Obviously, there is a great appeal for using one’s own natural growth factors to stimulate healing rather than relying on pharmaceutical injectables for symptom management.
Treatments that were only available for high profile athletes are now being promoted and advertised for use by the “weekend warrior” athlete and general population. Although many of these treatments may have great promise, traditional medical organizations have been somewhat slow to endorse them due to limited research, conflicting findings, and lack of
Researchers have been working diligently to better define the mechanism of injury and agingprocess in many musculoskeletal conditions. For example, osteoarthritis affects some 30 million adults in the United States. More than 600,000 total knee replacements are performed in the U.S. each year, and approximately 4.7 million Americans currently have undergone a total knee replacement, according to findings documented in 2014 by physicians at the Mayo Clinic.(1)
We all know someone who has osteoarthritis, which results in a gradual decline in the protective cartilage that forms the joint. The joint space and lubrication become ineffective, and one’s mobility and quality of life deteriorates with an endpoint frequently requiring a total joint replacement. There appear to be many contributing factors including genetics, one’s immune process, micro/macro injuries, and the body’s ability to respond to such challenges.
Fortunately, we are now able to concentrate particular cells and proteins found in one’s own blood, which, according to in vitro and animal studies, may decrease inflammation and promote repair of tissues.(2, 3) This process is a more refined approach than that which is available through traditional Platelet-Rich Plasma (PRP) and is the subject of an ongoing double-blind study sponsored by Zimmer Biomet called the PROGRESS IV clinical trial.
Campbell Clinic is proud to have been chosen as an investigational site for studying the use of the nSTRIDE® (4) APS modality in those with painful osteoarthritis in one knee. As with all well controlle studies, there are criteria that need to be met prior to clearance for patient participation. Eligible patients will be randomly assigned to receive an injection of the autologous protein solution (APS) or saline. If the individual cannot fulfill the requirements of the study, however, Campbell Clinic offers a multitude of other treatment options for managing symptoms associated with osteoarthritis.
For further information regarding the study, or to determine if you meet eligibility criteria, text 1KNEE to the number 87888, call (773) 313-3077, or visit http://www.zimmerbiomet.com/nstridetrial.
Dr. Santos Martinez specializes in Physical Medicine and
Rehabilitation/Sports Medicine at Campbell Clinic. For more information go to campbellclinic.com or call 901.759.5400.
1- Maradit Kremers H , et. al. Prevalence of total hip (THR) and
total knee (TKA) Arthroplasty in the United States. AAOS
Annual Meeting; 2014
2- O’Shaughnessey KM, et al. Blood-derived anti-inflammatory
protein solution blocks the effect of IL-1B on human
macrophages in vitro. Inflamm Res. (2011). 60: 929.
3- King W, et al. Human blood-based anti-inflammatory
solution inhibits osteoarthritis progression in a meniscal-tear
rat study. J Orthop Res. (2017). DOI 10.1002/jor.23528.
4- nSTRIDE is a registered trademark of Biomet Biologics, LLC